Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid

BACKGROUND: Early and accurate detection and staging is critical to managing Alzheimer’s disease (AD) and supporting clinical trials. Cerebrospinal fluid (CSF) biomarkers for amyloid-β peptides, tau species, and various neurodegenerative and inflammatory analytes are leading the way in this regard,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Alzheimers Dis
Hlavní autoři: Triana-Baltzer, Gallen, Van Kolen, Kristof, Theunis, Clara, Moughadam, Setareh, Slemmon, Randy, Mercken, Marc, Galpern, Wendy, Sun, Hong, Kolb, Hartmuth
Médium: Artigo
Jazyk:Inglês
Vydáno: IOS Press 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683057/
https://ncbi.nlm.nih.gov/pubmed/32831201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-200463
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky